REMARKS

Applicants respectfully request entry of the amendment and reconsideration of the claims. Claims 1 and 2 have been amended to further clarify the invention as claimed. Claims 10 and 11 are newly presented. After entry of the amendment, claims 1-11 will be pending. Claims 4-6, 8, and 9 have been withdrawn by the Examiner as drawn to a non-elected invention.

Applicants submit the amendment is supported throughout the specification, including for example the working examples at pages 16-134, and does not introduce any new matter.

Enablement

Claims 1-3 and 7 were rejected under 35 U.S.C. § 112, first paragraph as allegedly failing to comply with the enablement requirement. Applicants respectfully traverse this rejection.

The Office Action alleges the specification does not provide sufficient guidance to practice the scope of the claims without undue experimentation. Applicants respectfully do not agree.

An enabling disclosure requires a reasonable correlation to the scope of the claims. As long as the specification discloses at least one method for making and using the claimed invention that bears a reasonable correlation to the entire scope of the claim, then the enablement requirement is satisfied (*In re Fischer*, 427 F.2d 833, 839 (CCPA 1970)). For a claimed genus, representative examples coupled with a statement applicable to the genus as a whole are ordinary sufficient to comply with the enablement requirement (MPEP § 2164.02).

Claim 1 has been amended to recite that R_1 represents one atom or group of atoms selected from a hydrogen atom, the halogens, C_1-C_3 alkyl groups, or C_1-C_3 alkoxy groups, R_2 represents one atom or group of atoms selected from a hydrogen atom, the halogens, C_1-C_3 alkyl groups, C_1-C_3 alkoxy groups, or CF_3, R_3 represents one atom or group of atoms selected from a hydrogen atom, the halogens, C_1-C_3 alkyl groups, or C_1-C_3 alkoxy groups, R_4 represents one atom or group of atoms selected from a hydrogen atom or C_1-C_3 alkyl groups, and Y represents a saturated C_3-C_5 alkylene group interrupted by an oxygen. Applicants submit the guidance provided in the specification, including synthesis of at least 151 compounds and the description

of the processes that can be used to prepare the claimed compounds, is sufficient to enable the scope of the claims as amended. The claims as amended reasonably correlate to the scope of enablement specifically provided by the numerous working examples provided in the specification.

The disclosure of a test with every species covered by a claim is not necessary for establishing enablement under 35 U.S.C. § 112, first paragraph. *In re* Wands, 858 F.2d 731 (Fed. Cir. 1998). A substantial amount of experimentation is permissible if the experimentation is routine or if the specification provides a reasonable amount of guidance with respect to the direction in which the experimentation should proceed. *In re Wands*, 858 F.2d 731 (Fed. Cir. 1988) (emphasis added); see also *In re Angstadt*, 190 USPQ 214, 218 (CCPA 1976). In view of the guidance provided in the specification, the disclosure of at least 151 compounds, the description of processes for synthesizing the compounds, and the high level of skill in the art, Applicants submit any experimentation necessary to practice the scope of the claims as amended would be routine.

In view of the forgoing, Applicants submit one of skill in the art would be able to practice the scope of the claims as amended without undue experimentation. Withdrawal of the enablement rejection is respectfully requested.

Indefinite

Claim 7 was rejected under 35 U.S.C. § 112, second paragraph as being indefinite. The Office Action alleges the term "pharmaceutically acceptable addition salt" is not supported by the specification. Applicants respectfully do not agree.

Applicants describe addition salts of the compounds of formula I and therapeutic composition comprising said addition salts, for example, at page 3, lines 19-20 and page 3, line 24 to page 4, lines 6. Pharmaceutically acceptable addition salt is also supported by claim 7 as originally filed. Moreover, the term is commonly used and widely recognized by one of skill in the art. A pharmaceutically acceptable salt refers to a salt that retains the biological effectiveness of the free acid or base of a specified compound and is not biologically or otherwise undesirable. See for example, U.S. 4,879,303 at column 1 and U.S. 5,312,961 at column 4, lines 13-23.

In view of the forgoing, Applicants submit "pharmaceutically acceptable addition salts" are adequately supported in the specification. The term is commonly used and widely recognized by one of skill in the art. Withdrawal of the rejection is respectfully requested.

Conclusion

In view of the above amendments and remarks, Applicants respectfully request a Notice of Allowance. If the Examiner believes a telephone conference would advance the prosecution of this application, the Examiner is invited to telephone the undersigned at the below-listed telephone number.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903

Date: December 26, 2007

Eric E. DeMaster
Reg. No. 55,107
EED:lek